Results 21 to 30 of about 40,704 (273)

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

Clinical pharmacology and therapy, 2022
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition ...
Craig R. Lee, Jasmine A. Luzum, K. Sangkuhl, Roseann S. Gammal, M. Sabatine, C. Stein, D. Kisor, N. Limdi, Yee Ming Lee, S. Scott, J. Hulot, D. Roden, A. Gaedigk, K. Caudle, T. Klein, Julie A. Johnson, A. Shuldiner   +16 more
semanticscholar   +1 more source

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.

New England Journal of Medicine, 2021
BACKGROUND Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.
Yongjun Wang, Xia Meng, Anxin Wang, Xuewei Xie, Yuesong Pan, S. Johnston, Hao Li, P. Bath, Q. Dong, Anding Xu, J. Jing, Jinxi Lin, Siying Niu, Yilong Wang, Xingquan Zhao, Zixiao Li, Yong Jiang, Wei Li, Liping Liu, Jie Xu, L. Chang, Lihua Wang, Xianbo Zhuang, Jinguo Zhao, Yefang Feng, Honghao Man, Guozhong Li, Baojun Wang   +27 more
semanticscholar   +1 more source

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2022
Background Studies have demonstrated increased risk of major atherothrombotic events in CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with clopidogrel after percutaneous coronary intervention (PCI).
A. Beitelshees, Cameron D Thomas, P. Empey, G. Stouffer, D. Angiolillo, Francesco Franchi, S. Tuteja, N. Limdi, James C. Lee, Julio D. Duarte, R. Kreutz, T. Skaar, James C. Coons, Jay Giri, C. McDonough, Rachel A Rowland, J. Stevenson, T. Thai, M. Vesely, Jacob T. Wellen, Julie A. Johnson, A. Winterstein, L. Cavallari, Craig R. Lee   +23 more
semanticscholar   +1 more source

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy

Frontiers in Cardiovascular Medicine, 2022
Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin remains the standard of care for all patients undergoing percutaneous coronary intervention (PCI).
A. Nguyen, L. Cavallari, J. Rossi, G. Stouffer, Craig R. Lee   +4 more
semanticscholar   +1 more source

Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study

The Pharmacogenomics Journal, 2022
Variation within the CYP2C19 gene has been linked to differential metabolism of selective serotonin reuptake inhibitors (SSRIs). Pharmacogenetic recommendations based on the effect of CYP2C19 variants have been made available and are used increasingly by
A. Campos, Enda M. Byrne, B. Mitchell, N. Wray, P. Lind, J. Licinio, S. Medland, N. G. Martin, I. Hickie, M. Rentería   +9 more
semanticscholar   +1 more source

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19

Translational Psychiatry, 2021
Extensive migration has led to the necessity of knowledge regarding the treatment of migrants with different ethnical backgrounds. This is especially relevant for pharmacological treatment, because of the significant variation between migrant groups in ...
A. Koopmans, M. Braakman, D. Vinkers, H. Hoek, P. V. van Harten   +4 more
semanticscholar   +1 more source

CYP2C19 Genetic Polymorphism in the East of Iran: Its Association with the Severity and Pattern of Coronary Artery Disease [PDF]

Journal of Cardio-Thoracic Medicine, 2019
Introduction: Since there has been a dearth of research on the assessment of CYP2C19 polymorphism in the east of Iran (Khorasan provinces), this study aimed to detect, CYP2C19*2 and CYP2C19*3 allele frequencies among patients with coronary artery disease.
Mahdi Zahedi, Mahmoud Shabestari, Hossein Ayatollahi, Arash Gholoobi   +3 more
doaj   +1 more source

Distribution of a novel CYP2C haplotype in Native American populations

Frontiers in Genetics, 2023
The CYP2C19 gene, located in the CYP2C cluster, encodes the major drug metabolism enzyme CYP2C19. This gene is highly polymorphic and no-function (CYP2C19*2 and CYP2C19*3), reduced function (CYP2C19*9) and increased function (CYP2C19*17) star alleles ...
Vanessa Câmara Fernandes, Marco Antônio M. Pretti, Luiza Tamie Tsuneto, Maria Luiza Petzl-Erler, Guilherme Suarez-Kurtz   +4 more
doaj   +1 more source

The Prevalence of CYP2C19 Polymorphism in Patients with Symptomatic Intracranial Atherosclerosis. [PDF]

Cerebrovasc Dis Extra
Introduction: Clopidogrel and aspirin were proved to have benefit in symptomatic intracranial stenosis. CYP2C19 polymorphism (CYP2C19*1, CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles) affects efficacy of clopidogrel.
Kittipanprayoon S, Vorasayan P, Chutinet A, Chariyavilaskul P, Suwanwela NC.   +4 more
europepmc   +2 more sources

The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease. [PDF]

BMC Cardiovasc Disord
Background Genetic variations in the CYP2C19 gene, which encodes the major enzyme responsible for activating clopidogrel, may influence response to Clopidogrel antiplatelet therapy.
Haj Saleh N, A Youssef L.
europepmc   +2 more sources